Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)
Conditions
Brief summary
The primary endpoint is the 2-year progression-free survival (PFS) of patients with newly diagnosed stage-IE OAMZL treated with the experimental strategy
Detailed description
Feasibility, Tolerability of prolonged administration of doxycycline, Activity (overall response rate), Overall survival, Cp eradication rate, Infection re-occurrence rate, Assessment of prevalence of IRTA1 marker in OAMZL, Assessment of genetic lesions and gene expression changes in OAMZL and their possible relationship with Cp infection and response to treatment, Identification of possible SNPs associated with Cp infection in OAMZL patients, Identification of possible bacterial polymorphisms responsible for antibiotic resistance, infection recurrence or persistence
Interventions
DRUGDOXYCYCLINE
Sponsors
Association International Extranodal Lymphoma Study Group (IELSG)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the 2-year progression-free survival (PFS) of patients with newly diagnosed stage-IE OAMZL treated with the experimental strategy | — |
Secondary
| Measure | Time frame |
|---|---|
| Feasibility, Tolerability of prolonged administration of doxycycline, Activity (overall response rate), Overall survival, Cp eradication rate, Infection re-occurrence rate, Assessment of prevalence of IRTA1 marker in OAMZL, Assessment of genetic lesions and gene expression changes in OAMZL and their possible relationship with Cp infection and response to treatment, Identification of possible SNPs associated with Cp infection in OAMZL patients, Identification of possible bacterial polymorphisms responsible for antibiotic resistance, infection recurrence or persistence | — |
Countries
Italy
Outcome results
None listed